Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-7305
Fax+1 713-792-4297
Are you Dr. Ohanian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Maro Ohanian, DO is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma.
Education & Training
Baylor Scott & White Medical Center - Baylor College of Medicine (Temple)Fellowship, Hematology and Medical Oncology, 2009 - 2011
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2006 - 2009
Texas College of Osteopathic MedicineClass of 2006
Texas College of Osteopathic MedicineClass of 2006
Certifications & Licensure
FL State License 2021 - Present
TX State License 2009 - 2026
OK State License 2020 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi
Leukemia. 2025-02-25 - 2 citationsLong-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
Cancer. 2025-01-01 - KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.Irtiza N Sheikh, Shaikha AlQahtani, C Cameron Yin, David McCall, Branko Cuglievan
Pediatric Blood & Cancer. 2024-04-01
Authored Content
- 'The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine IsOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens ComparingOctober 2017
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory MyeloidOctober 2017
Press Mentions
What’s New in Leukemia Research?May 29th, 2024- HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
